Alto Neuroscience, Inc.
About Alto Neuroscience, Inc.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$63.2M
- Total assets
- $184.7M
- Market cap
- $640.8M
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $68.6M
- Operating income
- -$68.6M
- Income tax
- $0
- Net income
- -$61.4M
- EPS (basic)
- $-2.50
- EPS (diluted)
- $-2.50
Balance sheet
- Total assets
- $177.5M
- Current assets
- $169.3M
- Total liabilities
- $26.1M
- Current liabilities
- $10.0M
- Shareholders’ equity
- $151.5M
Cash flow
- Operating cash flow
- -$47.4M
- Investing cash flow
- -$2.1M
- Financing cash flow
- $135.7M
- Net cash flow
- $86.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $640.8M
- EPS (diluted)
- $-2.5
- Shares outstanding
- 32.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 2, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $63.2M.
- Trading 29% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Alto Neuroscience, Inc..
Write a review
News about Alto Neuroscience, Inc.
News & sentiment via Polygon.io
